Physician profile
Ravis Curry
NPI 1255535613
$1,443.43
in general payments reported to CMS, 2019-2025
30 companies · $155 in 2025
The $155 reported for 2025 was less than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $525 · 2020: $115 · 2021: $51.52 · 2022: $165 · 2023: $218 · 2024: $214 · 2025: $155.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $587.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $586.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $175.29 | 2019-2025 | Airsupra, Fasenra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $169.38 | 2019-2025 | Ofev |
| Merck Sharp & Dohme LLC | $106.86 | 2019-2025 | Zerbaxa, Capvaxive, Recarbrio |
| Glaxosmithkline, LLC. | $93.48 | 2019-2023 | Trelegy Ellipta |
| Harmony Biosciences LLC | $92.98 | 2023-2025 | Wakix |
| La Jolla Pharmaceutical Company | $78.93 | 2022-2023 | Giapreza |
| Novartis Pharmaceuticals Corporation | $76.03 | 2019-2020 | |
| Genentech USA, INC. | $72.22 | 2019-2023 | Xolair |
| Genzyme Corporation | $60.40 | 2022-2025 | |
| United Therapeutics Corporation | $45.02 | 2020-2024 | Tyvaso |
| Jazz Pharmaceuticals INC. | $39.36 | 2019-2024 | |
| Grifols USA, LLC | $38.48 | 2019 | |
| Philips North America LLC | $38.40 | 2021 | |
| Mallinckrodt Enterprises LLC | $36.98 | 2019 | |
| Mylan Specialty L.P. | $32.02 | 2024 | Yupelri |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $30.89 | 2025 | Dupixent |
| Paratek Pharmaceuticals, INC. | $29.25 | 2019 | |
| Ani Pharmaceuticals, INC. | $29.15 | 2023 | Purified Cortrophin Gel |
| Gilead Sciences, INC. | $22.26 | 2022 | |
| Baxter Healthcare | $21.13 | 2022 | |
| Portola Pharmaceuticals, LLC | $20.67 | 2019 | |
| Tetraphase Pharmaceuticals, INC. | $19.38 | 2019 | |
| Mallinckrodt Hospital Products INC. | $18.42 | 2020 | |
| Alexion Pharmaceuticals, INC. | $16.93 | 2019 | |
| Insmed, INC. | $16.24 | 2020 | |
| Amgen INC. | $14.47 | 2023 | Tezspire |
| Nuwellis, INC. | $12.75 | 2019 | |
| Pfizer INC. | $12.67 | 2022 | |
| Melinta Therapeutics, LLC | $12.42 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $10.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ravis Curry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.